A Journey from Pharma to Nutraceuticals – A conversation with Sundeep Dugar, co-founder BlueOakNx, on Dr. M Podcast
There is a particular kind of scientific mind that refuses to accept a discrepancy as noise. Most researchers, confronted with data that does not match their hypothesis, look for the error. Dr. Sundeep Dugar looks for the question.
It is a habit that has defined four decades of pharmaceutical discovery and produced more than 140 patents. It has also produced something rarer: a scientist who consistently stops mid-conversation to make sure credit goes to the team rather than the individual. He says it not as a formality but as a statement of how science actually moves.
Dr. Sundeep Dugar PhD, an award-winning pharmaceutical drug discovery expert with nearly 40 years of experience and over 100 patents, spent 16 years unraveling this exercise mimicry puzzle. What he discovered could transform how we approach aging and energy.
Why Trusting the Observation Over the Hypothesis Opened New Doors
His first project as a drug discovery chemist at Schering-Plough began with a simple instruction: equip a lab and find a drug. The era was statins. The entire industry was focused on inhibiting cholesterol synthesis inside the body. Nobody was looking at cholesterol arriving from food through the gut.
The discovery of ezetimibe aka Zetia, still the only approved cholesterol absorption inhibitor in the world after more than 30 years, did not come from a brilliant hypothesis. It came from a discrepancy. The compound was not hitting the target it was designed to hit, yet the animals were showing exactly the cholesterol reduction the team wanted. They asked a different question: if it is not working the way we thought, what is it actually doing?
The answer was intestinal absorption. The discrepancy pointed there, and the team followed it. That instinct, trusting the observation over the hypothesis, is the first thread. It runs through everything that follows.
Applying the Same Logic to an Entirely Different Model Led to Discovery
In 2009, data arrived from a small UC San Diego pilot study examining epicatechin, a compound in dark chocolate, with five patients exhibiting both serious heart failure and type 2 diabetes. After three months of epicatechin-enriched cocoa, skeletal muscle biopsies looked different. Cristae, the internal compartments of mitochondria essential for energy production, had recovered. Sarcomere structure that had resembled someone decades older, now looked like the muscle of a person in their forties.
There is something worth sitting with here. The molecule at the center of Dr. Dugar’s first career chapter, cholesterol, turns out to be the starting material for the system at the center of the second. Mitochondria convert cholesterol to pregnenolone, precursor to all steroid hormones. The compound that one career was built around blocking is the beginning of the pathway the next chapter spent unlocking. He mentions it with quiet wonder.